Expansion Opportunity Curia is actively expanding manufacturing capacity in Europe and North America, notably Glasgow in the UK and Albuquerque in the US, signaling increased demand for CDMO services and potential for new multi-site collaborations across drug substance and drug product operations.

Integrated Capabilities With end-to-end offerings from discovery through commercialization and integrated regulatory and analytical capabilities, Curia can position as a one-stop partner for complex biologics and small molecule programs, appealing to sponsors seeking streamlined development timelines.

Scale and Footprint A global network of 25 sites and a 3,500-strong workforce, coupled with ISO 9000 and enterprise systems like SAP and IBM Maximo, supports large-scale manufacturing programs and robust supply continuity, enabling pitches to mid- to late-stage programs requiring reliable capacity.

Recent Investments Recent capital investments, including $4M upgrades to API aseptic suites in Valladolid and notable capacity expansions, indicate a commitment to modernizing capabilities and sustaining high-quality aseptic manufacturing for complex therapies.

Market Positioning Recognition as Massachusetts Manufacturer of the Year and ongoing international expansion position Curia as a credible, award-winning partner with regional advantages in Europe and North America, offering prospects for co-development and strategic manufacturing alliances.